Phase II multicenter clinical study of lurbinectedin (PM01183) in selected advanced solid tumors
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: PHARMA MAR, SA
- Phase: II
- Execution start: 05/02/2018
- End of execution: 30/11/2019
- IP: JAVIER VALDIVIA BAUTISTA